Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-12-01T11:33:40.699Z Has data issue: false hasContentIssue false
  • English
  • Français

An unexpected benefit of palliative transfusion

Published online by Cambridge University Press:  15 April 2019

Etienne Rivière Open the ORCID record for Etienne Rivière [Opens in a new window]
Etienne Rivière*
Affiliation:
Internal Medicine and Infectious Diseases Department, University Hospital Center of Bordeaux, Pessac, France
*
Author for correspondence: Etienne Rivière, Internal Medicine and Infectious Diseases Department, University Hospital Center of Bordeaux, 1 avenue Magellan, 33604 Pessac, France. E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Essay/Personal Reflection
Information
Palliative & Supportive Care , Volume 17 , Issue 5 , October 2019 , pp. 616 - 617
Copyright
Copyright © Cambridge University Press 2019 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ianotto, J-C, Chauveau, A, Boyer-Perrard, F, et al. (2018) Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study. Haematologica 103, 438–446.Google Scholar
Lawless, S, McMullin, MF, Cuthbert, R, et al. (2016) (32)P in the treatment of myeloproliferative disorders. Ulster Medical Journal 85, 83–85.Google Scholar
Leitch, HA, Chase, JM, Goodman, TA, et al. (2010) Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy. Hematology and Oncology 28, 40–48.Google Scholar
Sherbeck, JP and Boss, RD (2016) Ethical questions about platelet transfusions at the end of life. AMA Journal of Ethics 18, 764–770.Google Scholar
To, THM, To, LB, and Currow, DC (2016). Can we detect transfusion benefits in palliative care patients? Journal of Palliative Medicine 19, 1110–1113.Google Scholar
Uceda Torres, ME, Rodríguez Rodríguez, JN, Sánchez Ramos, JL, et al. (2014) Transfusion in palliative cancer patients: A review of the literature. Journal of Palliative Medicine 17, 88–104.Google Scholar
Verstovsek, S, Mesa, RA, Gotlib, J, et al. (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. New England Journal of Medicine 366, 799–807.Google Scholar